<DOC>
	<DOC>NCT00254202</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.</brief_summary>
	<brief_title>Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia</brief_title>
	<detailed_description>Schizophrenia is a severe mental illness affecting an estimated 1% of the world's population. Patients with schizophrenia suffer from productive symptoms (e.g., hallucinations and delusions), and deficit symptoms (e.g., a reduction or absence of normal behaviors or emotions). Other symptoms include a reduced ability to recall and learn new information. Iloperidone is being development as a treatment for symptoms of schizophrenia. This trial will test the safety and efficacy of iloperidone in patients with an acute exacerbation of the disease.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Subject with schizophrenia. Subject must sign a written consent form. Clinically significant disease of the heart, kidneys, liver or gastrointestinal system Psychiatric disorder other than schizophrenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Atypical antipsychotic</keyword>
	<keyword>psychosis</keyword>
</DOC>